GTHX G1 Therapeutics Inc.

17.81
+0.1  (+1%)
Previous Close 17.71
Open 17.69
Price To Book 1.86
Market Cap 666240648
Shares 37,408,234
Volume 318,762
Short Ratio
Av. Daily Volume 294,580

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 preliminary data noted ORR 37-43% across two arms. No CRs. PFS 8.8mths (HR 0.52, p=0.0669) and 7.3mths (HR 0.49; p=0.0546) across two arms. Combined PFS 7.9mths (HR 0.50, p=0.0189).
Trilaciclib
Triple-negative breast cancer
Phase 1b/2 preliminary data due 2H 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 2 data released November 26, 2018. ORR trilaciclib 56.0%, placebo 63.5%.
Trilaciclib plus Tecentriq
First-line small-cell lung cancer
Phase 1b preliminary released at ASCO 2018 - 17% PR. Additional data due 2H 2019.
Lerociclib (G1T38) plus Faslodex
ER+ breast cancer
Phase 2 preliminary data December 19, 2018 noted ORR 13% vs placebo 23%. Additional data due 2019.
Trilaciclib
First-line small-cell lung cancer
Phase 2 preliminary data December 19, 2018 noted ORR 13% vs placebo 23%.
Trilaciclib
Second/third-line small-cell lung cancer
Phase 1/2 preliminary data due 2H 2019.
G1T48
ER+, HER2- breast cancer

Latest News

  1. G1 Therapeutics to Present at the 18th Annual Needham Healthcare Conference
  2. Edited Transcript of GTHX.O earnings conference call or presentation 28-Feb-19 9:30pm GMT
  3. G1 Therapeutics to Present at Cowen and Company 39th Annual Healthcare Conference
  4. G1 Therapeutics, Inc. (GTHX) Q4 2018 Earnings Conference Call Transcript
  5. G1 Therapeutics Reports Fourth Quarter and Full-Year 2018 Financial Results
  6. G1 Therapeutics to Host Investor Day 2019 on March 6, 2019
  7. G1 Therapeutics to Report Fourth Quarter and Full-Year 2018 Financial Results on February 28, 2019
  8. Glancy Prongay & Murray LLP Continues Investigation on Behalf of G1 Therapeutics, Inc. Investors (GTHX)
  9. Are Insiders Selling G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock?
  10. 5 Domestic Stocks to Gain From Thaw in Trade Talks
  11. G1 THERAPEUTICS Enters Oversold Territory
  12. From Iqvia to Red Hat: These execs raked in millions from stock sales in 2018
  13. G1 Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference
  14. Why G1 Therapeutics Got Hammered 42.6% Today
  15. G1 Therapeutics Investors Recoil, Analysts Bullish In Wake Of Trilaciclib Results
  16. G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib Showing Multi-Lineage Myelopreservation Benefits in 2nd-/3rd-Line Small Cell Lung Cancer
  17. G1 Therapeutics, Inc. (GTHX): Are Hedge Funds Right About This Stock?
  18. New Research Coverage Highlights G1 THERAPEUTICS, Schlumberger, Adient, Camping World, Nutanix, and CNH Industrial N.V — Consolidated Revenues, Company Growth, and Expectations for 2018